Build and buy: Chr. Hansen's strategy to solidify its microbiome business

October 15, 2021 | Case Study

Chr. Hansen is a key player in the nutritional and health ingredients landscape. In particular, the company's human health and probiotics segment is well-known for developing and launching a number of key probiotic strains like Lactobacillus rhamnosus and Bifidobacterium, BB-12. Over the years, the company has focused on building its internal R&D expertise, and it has developed a robust technology platform for probiotics production. Since 2020, it has also made notable acquisitions for gut microbiome modulation, namely HSO Health Care and UAS Labs for probiotic products as well as Jennewein Biotechnologie on the prebiotics side for human milk oligosaccharides.

About Lux Research

Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.

Already a Lux Client?

Sign In

Interested in Learning More?

Contact us to learn the benefits of becoming a Lux member.

Or call us now

For North America (Boston Headquarters)
+1 (617) 502-5300

For EMEA (Amsterdam)
+31 20 280 7900

For APAC (Singapore)
+65 6592-6978